Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Retrospective Analysis of COVID-19 mRNA Vaccine Breakthrough Infections – Risk Factors and Vaccine Effectiveness
Cong Liu, Junghwan Lee, Casey Ta, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Comparative Effectiveness of mRNA and Inactivated Whole-Virus Vaccines Against Coronavirus Disease 2019 Infection and Severe Disease in Singapore
M Premikha, Calvin J. Chiew, Wycliffe Enli Wei, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 8, pp. 1442-1445
Open Access | Times Cited: 73
Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
Sally B. Coburn, Elizabeth Humes, Raynell Lang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 6, pp. e2215934-e2215934
Open Access | Times Cited: 65
Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium
Veerle Stouten, Pierre Hubin, Freek Haarhuis, et al.
Viruses (2022) Vol. 14, Iss. 4, pp. 802-802
Open Access | Times Cited: 43
Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)
Paolo Basso, Corrado Negro, Luca Cegolon, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 336-336
Open Access | Times Cited: 38
Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses
Jeffrey Tomalka, Mehul S. Suthar, Steven G. Deeks, et al.
Nature Immunology (2022) Vol. 23, Iss. 3, pp. 360-370
Open Access | Times Cited: 38
Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US
Raynell Lang, Elizabeth Humes, Sally B. Coburn, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2236397-e2236397
Open Access | Times Cited: 33
Clinical manifestations of COVID‐19 breakthrough infections: A systematic review and meta‐analysis
Christine J. Lee, Wongi Woo, Ah Young Kim, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 9, pp. 4234-4245
Open Access | Times Cited: 31
The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data
Soonok Sa, Chae Won Lee, Sung Ryul Shim, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 320-320
Open Access | Times Cited: 29
COVID-19 Breakthrough Infection Among Vaccinated Population in the United Arab Emirates
Nihar Ranjan Dash, Hiba Jawdat Barqawi, Anas A. Obaideen, et al.
Journal of Epidemiology and Global Health (2023) Vol. 13, Iss. 1, pp. 67-90
Open Access | Times Cited: 11
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Yandi Zhang, Jo‐Lewis Banga Ndzouboukou, Mengze Gan, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24
Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults
Janna R. Shapiro, Rosemary Morgan, Sean X. Leng, et al.
Frontiers in Aging (2022) Vol. 3
Open Access | Times Cited: 11
The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program
Tinevimbo Shiri, Marc Evans, Carla Talarico, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 140-140
Open Access | Times Cited: 10
Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT1262b2 and after booster vaccination with BNT1262b2 or mRNA-1273: a population-based cohort study (COVIDENCE UK)
Giulia Vivaldi, David A. Jolliffe, Hayley Holt, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 10
COVID-19 breakthrough infections among people living with and without HIV: A statewide cohort analysis
Xueying Yang, Jiajia Zhang, Ziang Liu, et al.
International Journal of Infectious Diseases (2023) Vol. 139, pp. 21-27
Open Access | Times Cited: 5
Duration of protective immunity following COVID‐19 vaccination of individuals with underlying health conditions: A rapid review
Kieran Walsh, Helen O’Donnell, Mark O’Loughlin, et al.
Reviews in Medical Virology (2024) Vol. 34, Iss. 2
Open Access | Times Cited: 1
Presenting clinical symptoms of post-COVID-19 breakthrough infection: Predictors of mortality in a Middle Eastern population
Asma S. Albtoosh, Randa Farah, Khaled Al Oweidat, et al.
Vaccine X (2024) Vol. 18, pp. 100495-100495
Open Access | Times Cited: 1
Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021
Francesca Colavita, Silvia Meschi, Cesare Ernesto Maria Gruber, et al.
Frontiers in Medicine (2022) Vol. 8
Open Access | Times Cited: 8
SARS-CoV-2 Vaccine Alpha and Delta Variant Breakthrough Infections Are Rare and Mild but Can Happen Relatively Early after Vaccination
Jelissa Katharina Peter, Fanny Wegner, Severin Gsponer, et al.
Microorganisms (2022) Vol. 10, Iss. 5, pp. 857-857
Open Access | Times Cited: 8
COVID-19 infections post-vaccination by HIV status in the United States
Sally B. Coburn, Elizabeth Humes, Raynell Lang, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 11
Comparative Effectiveness of mRNA and Inactivated Whole Virus Vaccines against COVID-19 Infection and Severe Disease in Singapore
M Premikha, Calvin J. Chiew, Wycliffe Enli Wei, et al.
SSRN Electronic Journal (2021)
Closed Access | Times Cited: 11
Outcome of SARS-CoV-2 variant breakthrough infection in fully immunized solid organ transplant recipients
Reem S. Almaghrabi, Fatimah S. Alhamlan, Ashraf Dada, et al.
Journal of Infection and Public Health (2021) Vol. 15, Iss. 1, pp. 51-55
Open Access | Times Cited: 9
Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
Zhipeng Yan, Ming Yang, Ching‐Lung Lai
Frontiers in Drug Discovery (2022) Vol. 2
Open Access | Times Cited: 6
A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice
Pascal Brandys, Xavier Montagutelli, Irena Merenkova, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Interpretation of vaccine associated neurological adverse events: a methodological and historical review
Marija Cauchi, Harriet A. Ball, Yoav Ben–Shlomo, et al.
Journal of Neurology (2021) Vol. 269, Iss. 1, pp. 493-503
Open Access | Times Cited: 7
Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases
Yen–Ju Chen, Po‐Liang Cheng, Wen‐Nan Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top